Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma
- PMID: 24861664
- DOI: 10.1016/j.jvir.2014.04.014
Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma
Abstract
Purpose: To assess cost effectiveness of radioembolization versus conventional transarterial chemoembolization.
Materials and methods: The cost of radioembolization versus conventional transarterial chemoembolization was determined based on Medicare reimbursements. Three patient subgroups were defined based on the Barcelona Clinic Liver Cancer (BCLC) classification system (A, B, or C). Efficacy and safety outcomes after each procedure were obtained from the literature. A Monte Carlo case-based simulation was designed for 60 months in 250 patients in each subgroup. Survival was calculated based on average survival from the literature and the Monte Carlo model. The primary outcome was the cost effectiveness of radioembolization over transarterial chemoembolization by considering calculated survival.
Results: The costs approached $17,000 for transarterial chemoembolization versus $31,000 or $48,000 for unilobar or bilobar radioembolization, respectively. Based on the simulation, median estimated survival was greater with transarterial chemoembolization than radioembolization in BCLC-A and BCLC-B subgroups (40 months vs 30 months and 23 months vs 16 months, respectively, P = .001). However, in the BCLC-C subgroup, survival was greater with radioembolization than transarterial chemoembolization (13 months vs 17 months, P = .001). The incremental cost-effectiveness ratio of radioembolization over transarterial chemoembolization in the BCLC-C subgroup was $360 per month. The results were dependent on bilobar versus unilobar radioembolization and the total number of radioembolization procedures.
Conclusions: The model suggests radioembolization costs may be justified for patients with BCLC-C disease, whereas radioembolization may not be cost effective in patients with BCLC-A disease; however, many patients with BCLC-C disease have extensive disease precluding locoregional therapies. Secondary considerations may determine treatment choice in more borderline patients (BCLC-B disease) because there is no persistent survival benefit with radioembolization.
Copyright © 2014 SIR. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.J Vasc Interv Radiol. 2016 Jun;27(6):795-802. doi: 10.1016/j.jvir.2016.03.005. Epub 2016 Mar 31. J Vasc Interv Radiol. 2016. PMID: 27038686
-
Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients.Nucl Med Commun. 2016 Jun;37(6):646-9. doi: 10.1097/MNM.0000000000000486. Nucl Med Commun. 2016. PMID: 26905317
-
Transarterial chemoembolization and radioembolization.Semin Liver Dis. 2014 Nov;34(4):435-43. doi: 10.1055/s-0034-1394142. Epub 2014 Nov 4. Semin Liver Dis. 2014. PMID: 25369305 Review.
-
90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness.J Comp Eff Res. 2013 Jul;2(4):435-44. doi: 10.2217/cer.13.37. J Comp Eff Res. 2013. PMID: 24236684 Review.
-
Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.Trials. 2012 Aug 23;13:144. doi: 10.1186/1745-6215-13-144. Trials. 2012. PMID: 22913492 Free PMC article. Clinical Trial.
Cited by
-
Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma.Semin Intervent Radiol. 2024 Mar 14;41(1):48-55. doi: 10.1055/s-0044-1779714. eCollection 2024 Feb. Semin Intervent Radiol. 2024. PMID: 38495267 Review.
-
Efficacy of Yttrium-90 Transarterial Radioembolisation in Advanced Hepatocellular Carcinoma: An Experience With Hybrid Angio-Computed Tomography and Glass Microspheres.J Clin Exp Hepatol. 2024 May-Jun;14(3):101342. doi: 10.1016/j.jceh.2023.101342. Epub 2023 Dec 26. J Clin Exp Hepatol. 2024. PMID: 38283702
-
Ablation versus Radiation Segmentectomy for Small Liver Tumors.Semin Intervent Radiol. 2024 Jan 24;40(6):511-514. doi: 10.1055/s-0043-1777714. eCollection 2023 Dec. Semin Intervent Radiol. 2024. PMID: 38274221 Review.
-
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221. Health Technol Assess. 2023. PMID: 38149643 Free PMC article.
-
Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy?JHEP Rep. 2023 Apr 25;5(8):100781. doi: 10.1016/j.jhepr.2023.100781. eCollection 2023 Aug. JHEP Rep. 2023. PMID: 37456674 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical